Primary treatment options for high-risk/medically inoperable early stage NSCLC patients

Guy C. Jones, Jason D. Kehrer, Jenna Kahn, Bobby N. Koneru, Ram Narayan, Tarita O. Thomas, Kevin Camphausen, Minesh P. Mehta, Aradhana Kaushal

Research output: Contribution to journalReview articlepeer-review

46 Scopus citations

Abstract

Lung cancer is among the most common cancers worldwide and is the leading cause of cancer death in both men and women. For patients with early stage (American Joint Committee on Cancer T1-2, N0) non-small-cell lung cancer, the current standard of care is lobectomy with systematic lymph node evaluation. Unfortunately, patients with lung cancer often have medical comorbities, which may preclude the option of surgical resection. In such cases, a number of minimally invasive to noninvasive treatment options have gained popularity in the treatment of these high-risk patients. These modalities provide significant advantages, including patient convenience, treatment in an outpatient setting, and acceptable toxicities, including reduced impact on lung function and a modest risk of postprocedure chest wall pain. We provide a comprehensive review of the literature, including reported outcomes, complications, and limitations of sublobar resection with or without intraoperative brachytherapy, radiofrequency ablation, microwave ablation, percutaneous cryoablation, photodynamic therapy, and stereotactic body radiotherapy.

Original languageEnglish (US)
Pages (from-to)413-430
Number of pages18
JournalClinical Lung Cancer
Volume16
Issue number6
DOIs
StatePublished - Nov 2015
Externally publishedYes

Keywords

  • Intraoperative brachytherapy
  • Microwave ablation
  • Percutaneous cryotherapy
  • Photodynamic therapy
  • Radiofrequency ablation
  • SBRT
  • Stereotactic body radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'Primary treatment options for high-risk/medically inoperable early stage NSCLC patients'. Together they form a unique fingerprint.

Cite this